澳大利亚孕妇新冠、流感与百日咳疫苗接种安全性及覆盖率的队列研究
该回顾性队列纳入2020至2023年南澳19,098名孕妇,评估孕期接种流感、百日咳和新冠疫苗的安全性及影响因素。三种疫苗均未增加不良围产结局风险,且与早产、死产及产科并发症减少相关;年轻、经产、未婚及原住民孕妇接种率较低。
要点
- 孕期接种流感、百日咳和新冠疫苗未增加高血压疾病、绒毛膜羊膜炎等风险。
- 流感疫苗与早产风险降低13%相关,百日咳疫苗与死产减少近50%相关。
- 年轻、经产、未婚及原住民孕妇接种率较低,需针对性策略。
核心结论
- 孕期接种流感、百日咳和新冠疫苗安全且具有额外获益,但接种率存在持续不公平。
研究设计与样本
- 回顾性队列研究,纳入2020至2023年南澳妇女儿童医院分娩的19,098名孕妇。
主要发现
- 64.1%接种流感疫苗,74.1%接种百日咳疫苗,29.5%接种至少一剂新冠疫苗。
- 流感疫苗与早产风险降低13%相关;百日咳疫苗与早产减少17%、死产减少近50%相关。
- 新冠疫苗与早产风险降低相关(aHR 0.79,95%CI 0.68-0.92)。
- 流感疫苗(aRR 0.94,95%CI 0.91-0.98)和百日咳疫苗(aRR 0.89,95%CI 0.86-0.92)与至少一种产科并发症风险降低相关。
- 接种流感或百日咳疫苗的孕妇诊断妊娠期糖尿病略有增加;所接种疫苗母亲的新生儿复苏、早发型败血症和低Apgar评分发生率较低。
临床怎么用
- 应向孕妇推荐流感、百日咳和新冠疫苗接种以降低不良围产结局风险。
- 针对年轻、经产、未婚及原住民孕妇需采取文化安全的靶向策略提高接种率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The study aimed to evaluate the safety and impact of maternal influenza, pertussis, COVID-19 vaccine on perinatal outcomes and identify determinants of uptake among pregnant women in South Australia. METHODS: This retrospective cohort study included 19,098 pregnant women who delivered at the Women's and Children's Hospital in South Australia between 2020 to 2023. Cox proportional-hazards models estimated hazard ratios (HRs) for time-sensitive perinatal outcomes, and log-binomial models were used for time-independent outcomes. Poisson regression models were used to estimate adjusted prevalence ratios (aPRs) to identify factors influencing maternal vaccine uptake. RESULTS: Overall, 64.1% received influenza, 74.1% pertussis, and 29.5% received ≥1 COVID-19 dose during pregnancy. Maternal influenza, pertussis, and COVID-19 vaccination were not associated with increased risks of hypertensive disorders, chorioamnionitis, premature rupture of membranes, antepartum or postpartum haemorrhage, small-for-gestational-age, or low birthweight. Following maternal influenza vaccination, a 13% protective effect against preterm birth was observed, with similar reductions after pertussis (17% and nearly 50% fewer stillbirths) and COVID-19 vaccination (aHR 0.79, 95% CI 0.68-0.92). Both maternal influenza (aRR 0.94, 95% CI 0.91-0.98) and pertussis vaccination (aRR 0.89, 95% CI 0.86-0.92) were associated with a lower likelihood of experiencing at least one obstetric complication. A small increase in diagnosed gestational diabetes was observed among women vaccinated against influenza or pertussis. Neonatal outcomes were favourable, with lower rates of resuscitation, early-onset sepsis, and low Apgar scores among infants of vaccinated mothers. Younger, multiparous, unmarried, and First Nations women were less likely to be vaccinated, with lower uptake also observed among mothers whose infants were discharged to non-parental care. CONCLUSIONS: Findings reaffirm the safety and added benefits of maternal influenza, pertussis, and COVID-19 immunisation, and highlight persistent inequities in uptake that require targeted, culturally safe strategies to ensure equitable protection for all pregnant women and their infants.
引用
- Mohammed H, Andraweera P, Marshall HS, et al. A cohort study to assess the safety and coverage of COVID-19, influenza, and pertussis vaccine in Australian pregnant women. Vaccine. 2026. PMID: 42667899. doi:10.1016/j.vaccine.2026.129081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。